Lenalidomide, rituximab, and ibrutinib was effective as a first-line therapy for patients with follicular lymphoma and MZL. Orelabrutinib induced high response rates and sustained remission in relapsed or refractory marginal zone lymphoma, Axi-cel showed promising efficacy and safety in patients with relapsed or refractory indolent non-Hodgkin lymphomas. Two surrogate markers predicted treatment effect on eight-year progression-free survival in patients with extranodal MZL. The phase I/II study examined the use of the Bruton’s tyrosine kinase inhibitor in 385 patients. Umbralisib was approved to treat marginal zone lymphoma (MZL) and follicular lymphoma (FL).